These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 27217043)

  • 1. Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant.
    Minhas AS; Jiang Q; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Krol GD; Kaatz S; Froehlich JB; Barnes GD
    J Thromb Thrombolysis; 2016 Nov; 42(4):566-72. PubMed ID: 27217043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant.
    Hale ZD; Kong X; Haymart B; Gu X; Kline-Rogers E; Almany S; Kozlowski J; Krol GD; Kaatz S; Froehlich JB; Barnes GD
    J Thromb Thrombolysis; 2017 Feb; 43(2):283-288. PubMed ID: 27837309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy.
    Manzoor BS; Walton SM; Sharp LK; Galanter WL; Lee TA; Nutescu EA
    J Thromb Thrombolysis; 2017 Nov; 44(4):435-441. PubMed ID: 29027097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation.
    Jackevicius CA; Lu L; Ghaznavi Z; Warner AL
    Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007230. PubMed ID: 33541109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
    Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1417-1425. PubMed ID: 28735494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation.
    Brais C; Larochelle J; Turgeon MH; Blais L; Farand P; Perreault S; Letemplier G; Beauchesne MF
    J Pharm Pharm Sci; 2017; 20():8-14. PubMed ID: 28459661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors That Affect Time to Switch From Warfarin to a Direct Oral Anticoagulant After Change in the Reimbursement Criteria in Patients With Atrial Fibrillation.
    Park S; Je NK
    J Cardiovasc Pharmacol Ther; 2020 Jan; 25(1):57-64. PubMed ID: 31405298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National Trends in Ambulatory Oral Anticoagulant Use.
    Barnes GD; Lucas E; Alexander GC; Goldberger ZD
    Am J Med; 2015 Dec; 128(12):1300-5.e2. PubMed ID: 26144101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure.
    Andreu-Cayuelas JM; Pastor-Pérez FJ; Puche CM; Mateo-Martínez A; García-Alberola A; Flores-Blanco PJ; Valdés M; Lip GY; Roldán V; Manzano-Fernández S
    Rev Esp Cardiol (Engl Ed); 2016 Feb; 69(2):134-40. PubMed ID: 26607030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription frequency and predictors for the use of novel direct oral anticoagulants for secondary stroke prevention in the first year after their marketing in Europe--a multicentric evaluation.
    Luger S; Hohmann C; Kraft P; Halmer R; Gunreben I; Neumann-Haefelin T; Kleinschnitz C; Walter S; Haripyan V; Steinmetz H; Foerch C; Pfeilschifter W
    Int J Stroke; 2014 Jul; 9(5):569-75. PubMed ID: 24828272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.
    Essien UR; Holmes DN; Jackson LR; Fonarow GC; Mahaffey KW; Reiffel JA; Steinberg BA; Allen LA; Chan PS; Freeman JV; Blanco RG; Pieper KS; Piccini JP; Peterson ED; Singer DE
    JAMA Cardiol; 2018 Dec; 3(12):1174-1182. PubMed ID: 30484833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation.
    Lu Y; Branstad R; Karim RM; Asinger RW
    J Clin Pharm Ther; 2014 Dec; 39(6):628-36. PubMed ID: 25252149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation.
    Baker D; Wilsmore B; Narasimhan S
    Intern Med J; 2016 Jul; 46(7):792-7. PubMed ID: 27040617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation.
    Khan F; Huang H; Datta YH
    J Thromb Thrombolysis; 2016 Nov; 42(4):573-8. PubMed ID: 27520093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Stroke Prevention in Patients with Atrial Fibrillation in Real Clinical Practice, Emphasis on Efficacy and Safety of Anticoagulant Therapy].
    Novikova TN; Ashurov AB; Kiseleva MV; Plotnikova MO; Podoprigora EA; Sayganov SA; Khagush AL
    Kardiologiia; 2020 Mar; 60(4):54-61. PubMed ID: 32394858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of safety and efficacy for direct oral anticoagulation treatment of non-valvular atrial fibrillation in relation to renal function.
    Zou R; Tao J; Shi W; Yang M; Li H; Lin X; Yang S; Hua P
    Thromb Res; 2017 Dec; 160():41-50. PubMed ID: 29096154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacing warfarin with a novel oral anticoagulant: Risk of recurrent bleeding and stroke in patients with warfarin ineligible or failure in patients with atrial fibrillation (The ROAR study).
    Turagam MK; Parikh V; Afzal MR; Gopinathannair R; Lavu M; Kanmanthareddy A; Pillarisetti J; Reddy M; Atkins D; Bommana S; Jaeger M; Jeffery C; Mohanty S; Santangeli P; Cheng J; Di Biase L; Narasimhan C; Natale A; Lakkireddy D
    J Cardiovasc Electrophysiol; 2017 Aug; 28(8):853-861. PubMed ID: 28497899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin.
    Pundi KN; Perino AC; Fan J; Schmitt S; Kothari M; Szummer K; Askari M; Heidenreich PA; Turakhia MP
    J Am Heart Assoc; 2021 Dec; 10(23):e020904. PubMed ID: 34779243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.